Streetbeat News

Earnings

JNJ

Johnson & Johnson announced positive topline results for Nipocalimab in Phase 3 and Phase 2 studies for treating generalized Myasthenia Gravis (gMG) and Sjögren's Disease (SjD), respectively. Nipocalimab showed clinical efficacy in gMG, addressing a significant unmet need for effective and safe therapies. It is also the first anti-FcRn to demonstrate efficacy in SjD, a prevalent autoantibody disease lacking advanced treatments. Over the past year, Nipocalimab has shown effectiveness in four different autoantibody-driven diseases.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:07 pm

AMSC

GHM

JCSE

TKR

In Monday's pre-market session, several industrials stocks showed notable movements. JE Cleantech Hldgs, American Superconductor, Jet AI, AgEagle Aerial Sys, Graham, and Terran Orbital were among the gainers, with increases ranging from 6.05% to 7.8%. On the losing side, Pineapple Energy, Roma Green Finance, Nauticus Robotics, Timken, View, and Swvl Hldgs saw declines between 5.69% and 32.4%. Notably, Graham and Timken released their Q3 and Q4 earnings, respectively.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 1:06 pm

EVBG

NSSC

OST

In Monday's pre-market session, several Information Technology stocks showed notable movements. Everbridge, Datasea, Akerna, and WiSA Technologies were among the top gainers, with Everbridge leading at an 18.1% increase. NAPCO Security Technologies also rose by 9.18% following its Q2 earnings release. On the downside, Ostin Technology Group, Infobird Co, WaveDancer, ReAlpha Tech Corp, Remark Holdings, and Infrared Cameras Holdings experienced declines, with Ostin Technology Group dropping the most at 10.6%.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 1:06 pm

OCUP

Ocuphire Pharma, Inc. (NASDAQ:OCUP) presented clinical data from its ZETA-1 trial on APX3330 for diabetic retinopathy at the 21st Annual Angiogenesis, Exudation, and Degeneration 2024 Conference. The trial showed a reduction in disease worsening with 24 weeks of APX3330 treatment. Ocuphire plans to finalize the Phase 3 program protocol with the FDA, highlighting APX3330's potential as an oral treatment option for non-proliferative diabetic retinopathy.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:06 pm

CZOO

MBLY

PDD

TSLA

The article highlights the top 5 consumer discretionary stocks considered oversold based on their Relative Strength Index (RSI) values, indicating potential buying opportunities. These include Mobileye Global Inc. (MBLY), Cazoo Group Ltd (CZOO), WW International, Inc. (WW), Tesla, Inc. (TSLA), and PDD Holdings Inc. (PDD), with recent financial results and stock performance discussed for each.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 1:05 pm

ON Semiconductor Corp (ON) projects Q1 2024 revenue to be between $1.8B-$1.9B, below the estimated $1.92B, and adjusted EPS to range from $0.98-$1.10, potentially missing the $1.10 estimate. The forecast includes a GAAP gross margin of 44.4%-46.4%, operating expenses between $320M-$335M, and diluted EPS of $0.94-$1.06.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:05 pm

CANO

CHEA

FDMT

4D Molecular Therapeutics, Inc. (FDMT) shares rose by 20.1% in pre-market trading after presenting favorable interim data from a Phase 2 clinical trial. Other stocks also moved significantly in pre-market trading, with notable gainers including Chenghe Acquisition Co. (CHEA), Tritium DCFC Limited (DCFC), and YanGuFang International Group Co., Ltd. (YGF). Losers included Cano Health, Inc. (CANO), DMK Pharmaceuticals Corporation (DMK), and NanoString Technologies, Inc. (NSTG), all experiencing significant drops due to various challenges such as bankruptcy proceedings and delisting notices.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 1:04 pm

SPHR

Sphere Entertainment reported a Q2 adjusted EPS of $(1.59), which missed the estimated $(0.80).

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:04 pm

MLAB

Mesa Laboratories (NASDAQ:MLAB) reported Q3 earnings of $2.02 per share, significantly beating the $0.19 estimate but marking a 14.04% decrease from last year. Sales were $53.47M, missing the $54.89M estimate and showing a 1.50% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:02 pm

INSE

Inspired Entertainment, Inc. (INSE) has received approval from Nasdaq for its compliance plan to file the overdue Form 10-Q for Q3 2023 by February 28, 2024. The company is also working on filing restated financial statements for 2022 and the first two quarters of 2023 by the same deadline.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:01 pm